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Abstract
While the clinical progress of chimeric antigen receptor T cell (CAR-T) immunotherapy has 
garnered attention to the field, our understanding of the biology of these chimeric molecules is still 
emerging. Our aim within this review is to bring to light the mechanistic understanding of these 
multi-modular receptors and how these individual components confer particular properties to 
CAR-Ts. In addition, we will discuss extrinsic factors that can be manipulated to influence CAR-T 
performance such as choice of cellular population, culturing conditions and additional 
modifications that enhance their activity particularly in solid tumors. Finally, we will also consider 
the emerging toxicity associated with CAR-Ts. By breaking apart the CAR and examining the role 
of each piece, we can build a better functioning cellular vehicle for optimized treatment of cancer 
patients.
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Introduction
Chimeric antigen receptors (CARs) are fusion proteins where the binding site of a 
monoclonal antibody (Ab) is fused to intracellular signaling molecules. Upon engraftment in 
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T cells, CARs direct their antigen-specificity toward antigens expressed on the cell surface 
of tumor cells. CARs thereby provide T cells with major histocompatibility complex 
(MHC)-independent cytotoxic activity and co-stimulation impartial from ligands expressed 
by tumor cells.
Among cancer cell-based therapies, CAR T lymphocytes (CAR-Ts) are currently perceived 
as the most promising therapeutic approach as emphasized by the significant investment in 
CARTs by pharma companies. The clinical impact of CAR-Ts, especially for lymphoid 
malignancies, has been extensively summarized in other recent review articles (1–4). We 
will instead outline molecular aspects of the design of CAR molecules that affects their 
function as well as additional features of CAR-Ts. These emerging data should likely 
encourage investigators to revisit the bench to further assess the basic biology of these 
molecules and their effects on T cells upon engraftment to better understand clinical results.
The application of CAR-Ts in solid tumors is still in its infancy, but it is clear that the results 
in the clinical arena of solid tumors are not comparable to the experience in the lymphoid 
malignancy setting (5;6). This likely stems from solid tumors posing extra barriers of 
complexity as compared to liquid tumors. While the combination of CAR-Ts with other 
immunomodulatory or biological agents can overcome some of the extra barriers, in this 
review we will discuss how genetic engineering of CAR-Ts has been implemented to 
enhance their functions. The clinical success of CAR-Ts in solid tumors may require more 
efforts and multiple exploratory phase I studies to optimize a larger therapy scope, but there 
is no reason to lose enthusiasm for this technology in the more challenging solid tumor 
setting.
The great majority of effective anti-tumor agents cause side effects, and CAR-Ts do not 
make an exception as objective tumor regressions are frequently achieved with 
accompanying toxicities. Some of these toxicities were in some way anticipated, but others 
were unexpected. We will also discuss efforts that investigators are making to limit or 
contain the toxicities of CARTs.
1.1 CAR design
The antigen specificity of CARs is derived from mouse monoclonal Abs, humanized Abs or 
fully human Abs. Specifically, the variable regions of the heavy and light chains of Abs are 
cloned in the form of single-chain variable fragments (scFv) and joined through an hinge 
and a transmembrane domain to intracellular signaling molecules of the T-cell receptor 
(TCR) complex and co-stimulatory molecules. A significant amount of in vitro experiments 
indicate that CARs when sufficiently expressed on the cell surface of either CD4+ or CD8+ 
T cells can promote cytotoxic function as long as either the ζ-chain or the FcεRI of the TCR 
complex is included, and regardless of which molecular design is used to assemble the CAR. 
However, from their original introduction as T-bodies in the late eighties (7), the design of 
CAR molecules has evolved significantly in the past 10 years (8;9). Emerging data shows 
that the individual fragments included in these chimeric proteins can affect the functionality 
and survival of T lymphocytes. We outline below some of the developing preclinical and 
clinical data in which the specific design of CARs can be linked to T cell function or 
survival. For convenience, we have grouped these components into two sections, the 
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“Extracellular Region” that includes the signal peptide, the scFv and the hinge, and the 
“Intracellular Region” that includes the transmembrane domain and signaling domains 
(Figure 1).
1.1.1 Extracellular Region—The native signal peptide of a protein is an N-terminal short 
sequence necessary for the translocation of the nascent precursor protein to the endoplasmic 
reticulum membrane and to the secretory pathway. Although signal peptides of different 
proteins accomplish the same function in eukaryotic cells, their sequences are not highly 
conserved (10). In addition, the signal peptide is added “ectopically” to the scFv for the 
CAR assembling, and different sequences have been used. At the moment it is unknown if 
signal peptide sequences are more suitable for CAR assembly versus others.
The scFv is the portion of the CAR that determines its antigen specificity. It is fair to say 
that currently all the scFv used in preclinical and clinical studies to assemble CARs derive 
from Abs for which the sequences of the variable regions were known, or from Ab 
sequences obtained from available mouse hybridomas (8;9;11–14). Although conflicting 
results have been reported, it is becoming evident that we may need to revisit the use of 
available scFv for the generation of CARs and consider that new scFv must be generated and 
tailored to CAR application(15). First and foremost, the affinity of the scFv for the target 
antigen needs to be optimized for tumor antigens that can be expressed at low levels on 
normal tissues, in an attempt to minimize potential toxicities (16). In addition, since some 
target antigens can also be detected in soluble form at different levels in cancer patients, it 
may be relevant to consider the cloning of a scFv that has a greater affinity for the 
membrane bound form of the antigen rather than the soluble form, to enhance the specificity 
of the binding to tumor cells (13;17;18). In some instances it has been reported that the 
framework regions of specific scFv may cause a spontaneous antigen-independent signaling 
of CARs, leading to T cell exhaustion (19), or constitutive proliferation of CAR-Ts 
especially when CD28 is used as a co-stimulatory moiety (20). The clinical implications of 
these results remain conflicting, especially taking into consideration that a certain level of 
antigen-independent growth of CAR-Ts carrying the 4-1BB co-stimulatory moiety is 
considered a positive factor (21), and led to sustained clinical responses (3). The 
immunogenicity of scFv of mouse origin or junctional regions may also emerge as an 
obstacle for the long term persistence of CAR-Ts (22). While preconditioning regimens used 
in patients before the infusion of CAR-Ts may allow their survival for weeks, we cannot 
exclude the possibility of CAR-T rejection in immune reconstituted hosts by either B or T 
cells.
The hinge region of CARs has received significant attention in the past few years. The hinge 
has generally been considered a portion of the molecule empirically used to provide 
flexibility to the scFv. The addition of long hinges derived from human immunoglobulins 
(Igs) was also used as an opportunity to insert into CARs a fragment that could allow for 
their detection on the cell surface of T cells, particularly when Abs to detect the scFv were 
not functional or available (12;13;23). In the majority of cases, CAR-Ts show robust 
cytotoxic activity in in vitro experiments, regardless of the type of hinge used for the CAR 
assembly, and thus this component was not really considered to have any critical or specific 
function. However, it turned out that the hinge region can indeed have a significant impact 
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on CAR-T properties. For instance the length of the hinge derived from Igs may require 
optimization in relation to the location of the epitope within the molecule that the scFv is 
targeting (24;25). More surprisingly, hinge/spacer containing Fc portions of Igs included 
into CARs seem to retain some of their native properties in full antibodies. For instance the 
IgG1 Fc portion included into CARs can still bind with the Fc receptor expressed by 
monocytes/macrophages and cause their activation (26). In mouse experiments the reactivity 
of the IgG1 portion appears to reduce the anti-tumor activity of CAR-Ts likely due to the 
activation and exhaustion mediated by macrophages (27). An extra level of complexity as far 
as the hinge is concerned, is that in some CAR designs the hinge used does not belong to the 
Igs but to other molecules such the native hinge of the CD8α molecule (28). The CD8α 
hinge contains cysteine and proline residues known to play a role in the interaction of the 
CD8 co-receptor and MHC molecules, which may also not surprisingly affect CAR 
signaling. More basic signaling experiments are needed to fully discover the function of this 
fragment in CARs.
1.1.2 Intracellular Region—The transmembrane motif (TM) anchors the CAR to the 
plasma membrane. The native TM portion of CD28 is generally used in CARs in which 
CD28 also provides the co-stimulation, while the TM of CD8α is generally used when 
4-1BB is the co-stimulatory endodomain (28–30). We have previously observed that in 
CAR-Ts expressing only the ζ-chain without co-stimulatory domains the type of TM used 
(ζ vs. CD28) affects the stability of the surface CAR expression (9), but it remains 
unexplored if using CD28 versus CD8α TM may affect CAR assembling and signaling.
T cell activation requires at least two signaling events: the engagement of the TCR and a 
separate co-stimulatory signal. While T cells receive both signals by antigen-presenting 
cells, they usually do not receive co-stimulation by tumors lacking the ligands that engage 
the cognate co-stimulatory molecules. The design of CARs has quickly evolved from the 
simple incorporation of the ζ-chain (1st generation CARs) to the incorporation either of a 
single co-stimulatory domain (for example CD28 or 4-1BB)(2nd generation) (28;29;31), or 
the incorporation of two co-stimulatory endodomains (CD28/OX40 or CD28/4-1BB) (32;33) 
(3rd generation). Together with co-receptors such as CD8, these signaling moieties produce 
downstream activation of kinase pathways, which support gene transcription and functional 
cellular responses. The rational for adding co-stimulatory endodomains to CARs was 
supported by mechanistic studies showing activation of proximal signaling proteins related 
to either CD28 (Phosphatidylinositol-4,5-bisphosphate 3-kinase) or 4-1BB/OX40 (TNF-
receptor-associated-factor adapter proteins) pathways, and MAPK and Akt activation 
(29;32). In some models the use of a combination of early (CD28) and late (4-1BB/OX40) 
costimulatory molecules (3rd generation CARs) has evidenced a greater strength of signaling 
and persistence (33). However, it is also evident that this assumption does not apply to all 
circumstances, further underlining that the co-stimulation of CARs needs to be assessed in 
the context of all the other molecular components of the CAR, including its affinity to the 
target antigen and the structural characteristics of the targeted epitope. The clinical impact of 
the most suitable CAR co-stimulation still remains difficult to assess. In lymphoid 
malignancies targeted with CD19-specific CARs, while it is obvious that co-stimulation is 
required to promote T cell expansion (23), clinical responses in patients with acute 
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lymphoblastic leukemia are attainable with CARs containing either CD28 or 4-1BB 
(3;34;35). The long-term follow up of patients receiving CD19-specific CAR-Ts containing 
the 4-1BB without any additional treatment post T cell infusion shows long-term persistence 
and biological function of these cells, as demonstrated by the prolonged B cell aplasia (3). 
More recently, it has been suggested that 4-1BB co-stimulation, as compared to CD28, may 
promote longer survival of CAR-Ts by ameliorating the T cell exhaustion caused by 
persistent CAR signaling (19). Although a highly competitive scenario for the marketing of 
CD19-specific CAR-Ts is currently in place, proper comparative studies would help in 
defining the role of the specific co-stimulation. As far as solid tumors are concerned, clinical 
trials are still ongoing in different tumor settings using different CARs. These studies will be 
instrumental in assessing the role of CAR co-stimulation in solid tumors.
1.2 CAR-T products
1.2.1 Generation of CAR-T products for clinical use—In the most simplistic and 
frequently used approach, CAR-Ts are generated starting from unselected peripheral blood 
mononuclear cells that are activated using Abs specific for CD3 and CD28 either plate-
bound or on coated iron-beads (23;34;36;37). The delivery of the CAR transgene into 
activated T cells is generally achieved using either gamma-retroviral or lentiviral vectors 
(23;34;36;37). Currently there is no apparent clinical benefit from either type of vector, 
despite gamma-retroviruses and lentiviruses having significant intrinsic differences. In 
addition, gamma-retroviruses use the native virus promoter for CAR expression, while 
lentiviruses use an internal promoter for gene expression.
The methodology used for the in vitro expansion phase of CAR-Ts is also extremely 
variable between academic center in terms of media components and continuous CD3/CD28 
stimulations versus only cytokine supply. In general recombinant IL-2 is the most widely 
used growth factor to support T cell expansion (23;34;36;37). Most protocols aim at keeping 
CAR-Ts in culture less than 3 weeks to limit aging and loss of proliferative potential of the 
CAR-Ts once infused into patients. However, time of culture may vary due to the starting 
number of cells and the dose of T cells planned to be infused.
Non-viral gene transfer approaches, such as the Sleeping Beauty Transposon/Transposase 
System, are also used to transfer CARs. In general, given the relatively low efficiency of 
DNA integration, this method requires a longer period of culture for CAR-Ts to expand to 
numbers sufficient for infusion (38). Ongoing clinical trials will provide insights on whether 
this approach has comparable activity to viral-based gene transfer. Other non-viral gene 
delivery systems such as the prokaryotic type II CRISPR-Cas9 (clustered regularly 
interspaced short palindromic repeats CRISPR-associated 9) will significantly extend the 
ease in which the human genome can be edited in both stem cells and T lymphocytes (39).
1.2.1 CAR-T subsets and anti-tumor activity—The composition of T cell subsets of 
CAR-T products used in clinical trials is extremely heterogeneous. However, it seems 
appropriate to conclude that CAR-Ts expanded ex vivo and infused into patients are largely 
composed of a heterogeneous proportion of CD4+ and CD8+ T cells which have the 
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phenotypic characteristics of circulating effector (TEFF) and effector-memory (TEM) cells, 
while a minority resembles central-memory (TCM) cells (23;34;36;37).
The clinical experience with adoptive transfer of tumor infiltrating T lymphocytes (TILs) in 
melanoma patients and mouse models of adoptive T cell transfer are instrumental in 
clarifying the critical role of T cell subsets required for tumor responses. In TILs both 
telomere length and frequency of CD8+CD27+ T cells correlate with superior persistence 
and anti-tumor activity of these cells in patients (40). In an effort to maintain these biologic 
characteristics in the infused product, short-term culture approaches were implemented and 
moved to clinical practice (41). In mouse models, the engraftment and antitumor activity of 
tumor-specific T cells inversely correlate with the differentiation status of the infused cells, 
being naïve T cells (TN) superior to central memory TCM, and TCM superior to TEM(42). 
More recently another subset of mouse and human T cells, identified within the CD8 
compartment, defined T memory stem (TSCM) cells, was found to exhibit even more 
enhanced self-renewal and survival capacities and the multi-potent ability to derive all 
memory and effector T cell subsets (43). These properties make TSCM cells an ideal T cell 
population to employ in CAR-Ts in clinical trials, where therapeutic outcomes are highly 
dependent on engraftment and persistence of the transferred T cells. In the cell subset arena, 
we were the first to report that the presence of CD4+ T cells within the CAR-T products 
correlated with the in vivo persistence of GD2-specific CAR-Ts in patients with 
neuroblastoma (6). In lymphoma patients, we found that the number of 
CD8+CD45RA+CCR7+ CD19-specifc CAR-Ts, which resemble TSCM, highly correlated 
with superior in vivo expansion (44).
One of the challenges for the near future is to integrate these observations to generate better 
CAR-T products, whilst avoiding excessive complexity that can drastically reduce scalability 
of the process, and containing the manufacturing costs. Numerous cytokines profoundly 
affect T-cell development and differentiation. IL-2, IL-7, IL-15, and IL-21 are members of a 
cytokine family whose heteromeric receptors share the common γ chain (γc). Each cytokine 
has been described as a T-cell growth factor and each has been used to augment T-cell anti-
tumor immune responses. IL-2 is the predominant cytokine used for CAR-T manufacturing 
as for a long time was the only available clinical grade cytokine (3;23;34;36). We and others 
have found that in vitro IL-7 and IL-15 preserve a higher frequency of TSCM in CAR-Ts 
allowing for enhanced T cell persistence and anti-tumor activity in preclinical models 
(44;45). IL-7 and IL-15 instead of IL-2 have been recently incorporated in the manufacture 
CAR-Ts for clinical use. Similarly, exploring other cytokines may provide simple methods 
to generate more effective CAR-Ts. Investigators have also implemented a scalable approach 
to generate CAR-Ts starting from CD62L+ cells selected from the peripheral blood, 
followed by an adjustment of the ratio of CD4+ and CD8+ T cells in the final product (46). 
The development of automated and closed cell separation system may further facilitate the 
implementation of the genetic modification of desirable T cell subsets. Finally, taking in 
consideration that specific biologic characteristics of these subsets may have a favorable 
impact in specific tumors compared to total CD3+αδTCR+ polyclonal T cells, many 
investigators are pursuing other cell type for CARs engraftment, including virus-specific T 
cells (5;47), NK cells (48), γδT cells (49) and NKT cells (50).
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1.3 CAR-Ts and beyond
The successful use of CAR-Ts in lymphoblastic leukemia is likely partially contingent on 
choosing CD19 antigen as a target. The CD19 expression is indeed restricted to B 
lymphocytes and CD19-specific CAR-Ts encounter leukemic blasts or normal B 
lymphocytes immediately in the blood stream, thus receiving immediate activation, or in the 
bone marrow, where adoptively transferred T cells can reliably accumulate. By contrast, the 
selections of appropriate antigens and bio-distribution for CAR-Ts remain challenging in 
solid tumors. Several articles already underlined the critical role of antigen selection in solid 
tumor to minimize the damage or destruction of normal tissues (8;9;51), and thus we will 
only discuss studies in which CAR molecules have been coupled with other genes to 
enhance their functions.
1.3.1 CAR-T trafficking to tumors—In solid tumors, CAR-Ts circulating in the blood 
stream must extravasate to tumor sites and then counter a complex and frequently dynamic 
environment that can make CAR-Ts non-responsive. Taking into consideration the 
physiologic process of peripheral tissue infiltration of antigen-specific T cells in pathological 
conditions, such as inflammation, impaired migration and infiltration of CAR-Ts in solid 
tumors must account for some of the limited clinical benefits so far reported (5;6;52). 
Several preclinical examples have reported the feasibility of coupling CAR-Ts with 
chemokine receptors matched to the chemokine that tumor or stromal cells release, to allow 
specific and enhanced migration of CAR-Ts at the tumor site (53;54). CAR-Ts may also be 
modified to restore the expression of enzymes that digest components of the extracellular 
matrix and facilitate their infiltration within the stroma (55). Alternatively, CAR-Ts may be 
combined with other treatment modalities that help these cells to perfect their trafficking as 
recently demonstrated by using armed oncolytic viruses (56).
1.3.2 CAR-T survival and inhibition—When CAR-Ts effectively reach the tumor upon 
intravenous inoculation, several tumor escape mechanisms may then hamper and reduce 
their longevity or function within the tumor. Several additional genetic modifications of 
CAR-Ts have been reported to counter the plethora of inhibitory mechanisms that tumor 
cells employ to block immune responses. These genetic modifications can be summarized in 
strategies aimed at (1) directly promoting CAR-T survival, or (2) reverting or blocking 
tumor-associated inhibitory molecules.
Addition of cytokines or cytokine receptors have been proposed to create T cells with either 
an autonomous cytokine fuel or the capability to use surrounding cytokines. IL-2, IL-7, 
IL-15 and IL-21 have been coupled into CARs to promote the proliferation and survival of 
CAR-Ts (57;58). IL-15 is perhaps the most promising cytokine for partnering with CAR-Ts, 
to promote their local survival and growth while avoiding systemic toxicity. When expressed 
by CAR-Ts, IL-15 promotes T-cell proliferation, prevents apoptosis and exhaustion and 
overcomes T-cell inhibition mediated by regulatory T cells (57;59). Alternatively, CAR-Ts 
can be manipulated to express cytokine receptors such as IL-7Rα that sustain their 
proliferation in response to the homeostatic cytokine IL-7 (60).
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To revert or block tumor-associated inhibition, CAR-Ts have been coupled with the 
constitutive or inducible release of IL-12, although this last modification was only achieved 
by the use of two separated vectors (61;62). Ectopic expression of IL-12 by CAR-Ts 
promotes Th1 differentiation and helps in triggering the elimination of tumor-infiltrating 
macrophages, dendritic cells, and myeloid derived dendritic cells(63). Taking in 
consideration the blocking effects of Programmed Death PD ligand 1 (PD-L1) receptor, 
CAR-Ts have been engineered to transform the negative signal of PD-1 in T cells in a 
positive signal by substituting the intracytoplasmic domain of PD-1 with co-stimulatory 
signals (64).
1.4 CAR-Ts and toxicities
1.4.1 On-target toxicity and cytokine release syndrome—As evidenced in many 
effective treatments in cancer patients, objective tumor regressions in response to CAR-Ts 
are accompanied by toxicities. At the moment CAR-Ts pose two main safety concerns. The 
first relates to the inability of CAR-Ts to distinguish between tumor and normal tissues 
when the targeted antigen is shared between them (“on-target/off-tumor” toxicity). The 
second concern relates to the systemic perturbation of the immune system, known as 
cytokine release syndrome (CRS), systemic inflammatory response syndrome or cytokine 
storm, consequence of the rapid and robust in vivo expansion of CAR-Ts.
On-target toxicity such as B-cell aplasia induced by CD19-specific CAR-Ts was expected 
since the CD19 antigen is homogeneously expressed by both normal and malignant B 
lymphocytes (37). By contrast, the lethal on-target toxicity reported using a 3rd generation 
HER2/neu-specific CAR was unanticipated based on the safety data accumulated in clinical 
trials in which the same antigen was targeted using the monoclonal Ab trastuzumab (65). 
More recently, another clinical study showed that patients with osteosarcoma can be safely 
infused with T cells expressing a different 2nd generation HER-2/new-specific CAR (52). 
However, this second study did not show significant clinical benefits, and thus it remains to 
be confirmed whether a therapeutic window can be obtained with HER-2/new-specific 
CAR-Ts.
CRS is a clinical condition characterized by fever and hypotension that, in severe cases, 
leads to multiple organ failure. This toxicity correlates with the in vivo expansion of infused 
CAR-Ts, which causes a general perturbation of the immune system, and release of high 
levels of pro-inflammatory cytokines, such as TNF-α and IL-6 (37). This toxicity has been 
observed after the administration of CD19-specific CAR-Ts regardless of the CAR design or 
co-stimulation (either CD28 or 4-1BB) used.
1.4.2 Control on-target toxicity and cytokine release syndrome—Limiting or 
controlling on-target toxicities and CRS remains a critical aspect for the development of 
CAR-T therapies. On target toxicities are in general predictable in the case of antigens that 
are lineage-restricted in the hematopoietic system and hematologic malignancies since the 
expression profile of these antigens have been extensively characterized. By contrast, the on-
target toxicity remains challenging when pursuing antigens in solid tumors since, with few 
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exceptions, molecules overexpressed by tumor cells are also found, although at different 
levels, in some normal tissues.
To prevent on-target toxicities, the accurate screening of the antigen expression in different 
tissues is critical and can be facilitated by taking into account the publically available mRNA 
and protein Atlas (51). It is however also important to consider that different Abs with the 
same antigen-specificity may have different reactivity and thus the screening for the antigen 
expression must be performed using the same antibody from which the scFv of the CAR is 
derived. As mentioned in the CAR design paragraph, the screening of scFv with different 
affinities may help in discriminating between normal and tumor cells expressing different 
levels of the antigen, although this may also increase the chance of tumor escape.
The assessment of the potential toxicity of CAR-Ts targeting antigens shared with normal 
tissues can be facilitated in the clinical setting by the infusion of T cells that transiently 
express the CAR, for example after electroporation of mRNA encoding the receptor (66). In 
addition, there are significant efforts to further engineer CAR-Ts by including safety 
switches that allow the drastic elimination of CAR-Ts in case of severe on-target toxicity. 
Vectors in which a CAR is combined with safety switches, such as the inducible caspase9 
gene (67) (activated by a chemical inducer of dimerization) or a truncated form of the EGF 
receptor R (activated by the monoclonal antibody cetuximab) (68), are currently in clinical 
trials.
In further preclinical assessments, investigators have proposed to control the on-target 
toxicity by allowing CAR-Ts to exploit their full cytotoxic function only when an 
appropriate combination of antigens is recognized in tumor cells as compared to normal 
cells (69), or combining inhibitory chimeric antigen receptors (iCARs) to self-regulate 
CAR-T effector function taking advantage of the physiologic inhibitory effects of PD-1 and 
CTLA-4 (70). The elegant modeling used in these preclinical studies can be recapitulated 
within the heterogeneous human malignancies however need further validation in clinical 
studies.
The CRS toxicity caused by CAR-Ts poses a different level of attention as compared to on-
target toxicities and may require different approaches to be controlled. While severe on-
target toxicities for non-hematopoietic tissues are life threatening side effect that must be 
avoided, clinical data indicates that CRS is frequently associated with ongoing effective 
clinical responses (34;37). However, severe CRS can be lethal if not effectively controlled. 
Blocking the IL-6 receptor using the clinically available anti-IL-6 Ab tocilizumab has been 
used to successfully control severe CRS (3;71), but the development of alternative strategies 
that can more precisely control the dynamic of CAR-T expansion in vivo is desirable. Safety 
switches that rapidly eliminate CAR-Ts can also be effective in controlling CRS. For 
instance, it was recently reported that a clinical scenario resembling CRS occurring after 
allogeneic stem cell transplant was rapidly controlled by the selective in vivo activation of 
the inducible caspase9 (72). However, while the complete elimination of CAR-Ts is 
desirable to control potentially lethal on-target toxicities, the total elimination of CAR-Ts in 
patients developing severe CRS is not desirable since this will also compromise the ongoing 
anti-tumor effects. The activity of the inducible caspase9 as compared to all other clinically 
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available safety switches can be pharmacologically modulated by dosing the CID (73) and 
may thus provide means to control CRS without completely abrogating CAR-Ts. Finally, 
recent effort to generate CARs in which intracellular signaling are controlled by small 
molecules that allow heterodimerization of the signaling components may further create 
CAR-Ts in which proliferation and effector function can be tightly controlled(74).
Conclusions
CAR-Ts and checkpoint inhibitors are conquering a significant space in the treatment of 
patients with a variety of malignancies. While we find that some tumors are more 
susceptible than other to immunotherapy approaches, a better understanding of the 
mechanisms underlining the clinical success or failure of checkpoint regulations are critical 
to continue implementing more advanced strategies. This concept is particularly true for 
CAR-Ts a scenario where a more rational and systematic approach in designing and 
assessing the functionality of these molecules can only be guided by a more precise 
definition of how these molecules interact with the complex network of T cell signaling, 
activation and differentiation. In addition, CAR-Ts likely need to be associated with other 
biological components or molecules to achieve robust clinical benefits in patients with solid 
tumors.
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Highlights
• Examination of key molecular attributes of CARs that influence 
functionality
• Factors to consider in building a CAR
• Coupling CARs with additional molecules to enhance their function
• CAR-T toxicities
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Figure 1. Construction of CAR molecules
Schematic representation and functional characterization of CAR molecules
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